Verzenio加荷尔蒙疗法使高危早期乳腺癌患者的死亡风险降低15.8%,试验显示。 Verzenio plus hormone therapy cut death risk by 15.8% in high-risk early breast cancer patients, trial shows.

Elilly宣布,根据MonarchE试验的主要总体生存分析,其药物Verzenio与内分泌疗法结合了两年后,将高风险乳腺癌早期患者的死亡风险降低了15.8%。 Eli Lilly announced that its drug Verzenio, when combined with endocrine therapy for two years, reduced the risk of death by 15.8% in high-risk early breast cancer patients, according to the MonarchE trial's primary overall survival analysis. 经过6.3年的中位跟踪后,治疗显示存活率持续改善,复发率减少,没有新的安全关切。 After a median follow-up of 6.3 years, the treatment showed sustained improvements in survival and reduced recurrence, with no new safety concerns. 其结果发表在肿瘤学年鉴上,并在ESOM年度会议上介绍,这是20多年来该患者群体首次获得重大生存福利,并将Verzenio定为新的护理标准。 The results, published in Annals of Oncology and presented at the ESMO Annual Meeting, mark the first significant survival benefit in this patient group in over two decades and establish Verzenio as a new standard of care.